Ionizable lipid serves as the key functional component
in lipid
nanoparticles (LNPs) for efficient mRNA delivery. This study aims
to systematically evaluate clinically approved ionizable lipid DLin-MC3-DMA
and SM102-based LNPs for ocular mRNA delivery, with a comprehensive
assessment of their physicochemical characteristics, delivery efficiency,
and biodistribution patterns within the ocular microenvironment. Enhanced
green fluorescence protein or Luc encoding mRNA-loaded LNPs were formulated
using microfluidic mixing technology and characterized by dynamic
light scattering, ζ-potential measurements, and cryogenic transmission
electron microscopy imaging. The two LNP systems with different ionizable
cationic lipids demonstrated distinct capabilities for in
vitro mRNA transfection and intraocular mRNA delivery following
intravitreal administration. Notably, the SM102-LNPs exhibited superior
performance compared to the MC3-LNPs, characterized by significantly
higher transfection efficiency in retinal cells in vitro, and more efficient ocular expression with minimal systemic distribution in vivo. Safety assessment demonstrated that intravitreal
administration of SM102-LNPs maintained excellent long-term biocompatibility
throughout a five-month study period. The superior performance of
SM102-LNPs establishes a promising platform for ocular mRNA therapeutics.